Ann Hepatobiliary Pancreat Surg.  2022 Feb;26(1):1-16. 10.14701/ahbps.22-009.

Korean Surgical Practice Guideline for Pancreatic Cancer 2021: A summary of evidence-based surgical approaches

• Lee SE
• Han SS
• Kang CM
• Kwon W
• Paik KY
• Song KB
• Yang JD
• Chung JC
• Jeong CY
• Kim SW

• KMID: 2526842
• DOI: http://doi.org/10.14701/ahbps.22-009

Abstract

Pancreatic cancer is the eighth most common cancer and the fifth most common cause of cancer-related deaths in Korea. Despite the increasing incidence and high mortality rate of pancreatic cancer, there are no appropriate surgical practice guidelines for the current domestic medical situation. To enable standardization of management and facilitate improvements in surgical outcome, a total of 10 pancreatic surgical experts who are members of Korean Association of Hepato-Biliary-Pancreatic Surgery have developed new recommendations that integrate the most up-to-date, evidence-based research findings and expert opinions. This is an English version of the Korean Surgical Practice Guideline for Pancreatic Cancer 2021. This guideline includes 13 surgical questions and 15 statements. Due to the lack of high-level evidence, strong recommendation is almost impossible. However, we believe that this guideline will help surgeons understand the current status of evidence and suggest what to investigate further to establish more solid recommendations in the future.

Keyword

Pancreatic carcinoma; Surgery; Practice guideline

Reference

1. Hong S, Won YJ, Park YR, Jung KW, Kong HJ, Lee ES. 2020; Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2017. Cancer Res Treat. 52:335–350. DOI: 10.4143/crt.2020.206. PMID: 32178489. PMCID: PMC7176962.

2. Ducreux M, Cuhna AS, Caramella C, Hollebecque A, Burtin P, Goéré D, et al. 2015; Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 26 Suppl 5:v56–v68. Erratum in: Ann Oncol 2017;28 Suppl 4:iv167-iv168. DOI: 10.1093/annonc/mdv295. PMID: 26314780.

3. Okusaka T, Nakamura M, Yoshida M, Kitano M, Uesaka K, Ito Y, et al. 2020; Clinical Practice Guidelines for pancreatic cancer 2019 from the Japan Pancreas Society: a synopsis. Pancreas. 49:326–335. DOI: 10.1097/MPA.0000000000001513. PMID: 32132516. PMCID: PMC7077959.

4. Tempero MA, Malafa MP, Al-Hawary M, Behrman SW, Benson AB, Cardin DB, et al. 2021; Pancreatic Adenocarcinoma, version 2.2021, NCCN Clinical Practice Guidelines in oncology. J Natl Compr Canc Netw. 19:439–457. DOI: 10.6004/jnccn.2021.0017. PMID: 33845462.

5. Committee of the Korean clinical practice guideline for pancreatic cancer and National Cancer Center, Korea. Korean clinical practice guideline for pancreatic cancer 2021: a summary of evidence-based, multi-disciplinary diagnostic and therapeutic approaches. Pancreatology. 2021; 21:1326–1341. DOI: 10.1016/j.pan.2021.05.004. PMID: 34148794.

6. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. 2011; The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 343:d5928. DOI: 10.1136/bmj.d5928. PMID: 22008217. PMCID: PMC3196245.

7. Kim SY, Park JE, Lee YJ, Seo HJ, Sheen SS, Hahn S, et al. 2013; Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity. J Clin Epidemiol. 66:408–414. DOI: 10.1016/j.jclinepi.2012.09.016. PMID: 23337781.

8. Shea BJ, Hamel C, Wells GA, Bouter LM, Kristjansson E, Grimshaw J, et al. 2009; AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews. J Clin Epidemiol. 62:1013–1020. DOI: 10.1016/j.jclinepi.2008.10.009. PMID: 19230606.

9. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. 2011; QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 155:529–536. DOI: 10.7326/0003-4819-155-8-201110180-00009. PMID: 22007046.

10. Brouwers MC, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, et al. 2010; Development of the AGREE II, part 1: performance, usefulness and areas for improvement. CMAJ. 182:1045–1052. DOI: 10.1503/cmaj.091714. PMID: 20513780. PMCID: PMC2900328.

11. Brouwers MC, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, et al. 2010; Development of the AGREE II, part 2: assessment of validity of items and tools to support application. CMAJ. 182:E472–E478. DOI: 10.1503/cmaj.091716. PMID: 20513779. PMCID: PMC2900368.

12. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. 2008; GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 336:924–926. DOI: 10.1136/bmj.39489.470347.AD. PMID: 18436948. PMCID: PMC2335261.

13. Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schünemann HJ. 2008; What is "quality of evidence" and why is it important to clinicians? BMJ. 336:995–998. DOI: 10.1136/bmj.39490.551019.BE. PMID: 18456631. PMCID: PMC2364804.

14. Sell NM, Fong ZV, Del Castillo CF, Qadan M, Warshaw AL, Chang D, et al. 2018; Staging laparoscopy not only saves patients an incision, but may also help them live longer. Ann Surg Oncol. 25:1009–1016. DOI: 10.1245/s10434-017-6317-1. PMID: 29388123.

15. Schnelldorfer T, Gagnon AI, Birkett RT, Reynolds G, Murphy KM, Jenkins RL. 2014; Staging laparoscopy in pancreatic cancer: a potential role for advanced laparoscopic techniques. J Am Coll Surg. 218:1201–1206. DOI: 10.1016/j.jamcollsurg.2014.02.018. PMID: 24698487.

16. Ahmed SI, Bochkarev V, Oleynikov D, Sasson AR. 2006; Patients with pancreatic adenocarcinoma benefit from staging laparoscopy. J Laparoendosc Adv Surg Tech A. 16:458–463. DOI: 10.1089/lap.2006.16.458. PMID: 17004868.

17. Contreras CM, Stanelle EJ, Mansour J, Hinshaw JL, Rikkers LF, Rettammel R, et al. 2009; Staging laparoscopy enhances the detection of occult metastases in patients with pancreatic adenocarcinoma. J Surg Oncol. 100:663–669. DOI: 10.1002/jso.21402. PMID: 19780095.

18. Paracha M, Van Orden K, Patts G, Tseng J, McAneny D, Sachs T. 2019; Opportunity lost? Diagnostic laparoscopy in patients with pancreatic cancer in the national surgical quality improvement program database. World J Surg. 43:937–943. DOI: 10.1007/s00268-018-4855-8. PMID: 30478680.

19. Yamamura K, Yamashita YI, Yamao T, Kuroda D, Eto T, Kitano Y, et al. 2020; Efficacy of staging laparoscopy for pancreatic cancer. Anticancer Res. 40:1023–1027. DOI: 10.21873/anticanres.14037. PMID: 32014948.

20. Ta R, O'Connor DB, Sulistijo A, Chung B, Conlon KC. 2019; The role of staging laparoscopy in resectable and borderline resectable pancreatic cancer: a systematic review and meta-analysis. Dig Surg. 36:251–260. DOI: 10.1159/000488372. PMID: 29649825.

21. De Rosa A, Cameron IC, Gomez D. 2016; Indications for staging laparoscopy in pancreatic cancer. HPB (Oxford). 18:13–20. DOI: 10.1016/j.hpb.2015.10.004. PMID: 26776846. PMCID: PMC4750228.

22. Pisters PW, Lee JE, Vauthey JN, Charnsangavej C, Evans DB. 2001; Laparoscopy in the staging of pancreatic cancer. Br J Surg. 88:325–337. DOI: 10.1046/j.1365-2168.2001.01695.x. PMID: 11260096.

23. Choi M, Hwang HK, Rho SY, Lee WJ, Kang CM. 2020; Comparing laparoscopic and open pancreaticoduodenectomy in patients with pancreatic head cancer: oncologic outcomes and inflammatory scores. J Hepatobiliary Pancreat Sci. 27:124–131. DOI: 10.1002/jhbp.697. PMID: 31705719.

24. Croome KP, Farnell MB, Que FG, Reid-Lombardo KM, Truty MJ, Nagorney DM, et al. 2014; Total laparoscopic pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: oncologic advantages over open approaches? Ann Surg. 260:633–638. discussion 638–640. DOI: 10.1097/SLA.0000000000000937. PMID: 25203880.

25. Girgis MD, Zenati MS, King JC, Hamad A, Zureikat AH, Zeh HJ, et al. 2021; Oncologic outcomes after robotic pancreatic resections are not inferior to open surgery. Ann Surg. 274:e262–e268. DOI: 10.1097/SLA.0000000000003615. PMID: 31663967. PMCID: PMC8683907.

26. Kuesters S, Chikhladze S, Makowiec F, Sick O, Fichtner-Feigl S, Hopt UT, et al. 2018; Oncological outcome of laparoscopically assisted pancreatoduodenectomy for ductal adenocarcinoma in a retrospective cohort study. Int J Surg. 55:162–166. DOI: 10.1016/j.ijsu.2018.05.026. PMID: 29807171.

27. Stauffer JA, Coppola A, Villacreses D, Mody K, Johnson E, Li Z, et al. 2017; Laparoscopic versus open pancreaticoduodenectomy for pancreatic adenocarcinoma: long-term results at a single institution. Surg Endosc. 31:2233–2241. DOI: 10.1007/s00464-016-5222-1. PMID: 27604369.

28. Zhou W, Jin W, Wang D, Lu C, Xu X, Zhang R, et al. 2019; Laparoscopic versus open pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: a propensity score matching analysis. Cancer Commun (Lond). 39:66. DOI: 10.1186/s40880-019-0410-8. PMID: 31661036. PMCID: PMC6819395.

29. Adam MA, Choudhury K, Dinan MA, Reed SD, Scheri RP, Blazer DG 3rd, et al. 2015; Minimally invasive versus open pancreaticoduodenectomy for cancer: practice patterns and short-term outcomes among 7061 patients. Ann Surg. 262:372–377. DOI: 10.1097/SLA.0000000000001055. PMID: 26158612.

30. Jiang YL, Zhang RC, Zhou YC. 2019; Comparison of overall survival and perioperative outcomes of laparoscopic pancreaticoduodenectomy and open pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: a systematic review and meta-analysis. BMC Cancer. 19:781. DOI: 10.1186/s12885-019-6001-x. PMID: 31391085. PMCID: PMC6686510.

31. Peng L, Zhou Z, Cao Z, Wu W, Xiao W, Cao J. 2019; Long-term oncological outcomes in laparoscopic versus open pancreaticoduodenectomy for pancreatic cancer: a systematic review and meta-analysis. J Laparoendosc Adv Surg Tech A. 29:759–769. DOI: 10.1089/lap.2018.0683. PMID: 30835156.

32. Yin Z, Jian Z, Hou B, Jin H. 2019; Surgical and oncological outcomes of laparoscopic versus open pancreaticoduodenectomy in patients with pancreatic duct adenocarcinoma. Pancreas. 48:861–867. DOI: 10.1097/MPA.0000000000001363. PMID: 31306305.

33. Chen K, Zhou Y, Jin W, Zhu Q, Lu C, Niu N, et al. 2020; Laparoscopic pancreaticoduodenectomy versus open pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: oncologic outcomes and long-term survival. Surg Endosc. 34:1948–1958. DOI: 10.1007/s00464-019-06968-8. PMID: 31317331.

34. Lee SH, Kang CM, Hwang HK, Choi SH, Lee WJ, Chi HS. 2014; Minimally invasive RAMPS in well-selected left-sided pancreatic cancer within Yonsei criteria: long-term (>median 3 years) oncologic outcomes. Surg Endosc. 28:2848–2855. DOI: 10.1007/s00464-014-3537-3. PMID: 24853839.

35. Sulpice L, Farges O, Goutte N, Bendersky N, Dokmak S, Sauvanet A, et al. 2015; Laparoscopic distal pancreatectomy for pancreatic ductal adenocarcinoma: time for a randomized controlled trial? Results of an all-inclusive national observational study. Ann Surg. 262:868–873. DOI: 10.1097/SLA.0000000000001479. PMID: 26583678.

36. van Hilst J, de Rooij T, Klompmaker S, Rawashdeh M, Aleotti F, Al-Sarireh B, et al. 2019; Minimally invasive versus open distal pancreatectomy for ductal adenocarcinoma (DIPLOMA): a pan-European propensity score matched study. Ann Surg. 269:10–17. DOI: 10.1097/SLA.0000000000002561. PMID: 29099399.

37. Zhang M, Fang R, Mou Y, Chen R, Xu X, Zhang R, et al. 2015; LDP vs ODP for pancreatic adenocarcinoma: a case matched study from a single-institution. BMC Gastroenterol. 15:182. DOI: 10.1186/s12876-015-0411-2. PMID: 26695506. PMCID: PMC4687064.

38. Anderson KL Jr, Adam MA, Thomas S, Roman SA, Sosa JA. 2017; Impact of minimally invasive vs. open distal pancreatectomy on use of adjuvant chemoradiation for pancreatic adenocarcinoma. Am J Surg. 213:601–605. DOI: 10.1016/j.amjsurg.2017.01.005. PMID: 28093119.

39. Kantor O, Bryan DS, Talamonti MS, Lutfi W, Sharpe S, Winchester DJ, et al. 2017; Laparoscopic distal pancreatectomy for cancer provides oncologic outcomes and overall survival identical to open distal pancreatectomy. J Gastrointest Surg. 21:1620–1625. DOI: 10.1007/s11605-017-3506-y. PMID: 28766272.

40. Riviere D, Gurusamy KS, Kooby DA, Vollmer CM, Besselink MG, Davidson BR, et al. 2016; Laparoscopic versus open distal pancreatectomy for pancreatic cancer. Cochrane Database Syst Rev. 4:CD011391. DOI: 10.1002/14651858.CD011391.pub2. PMID: 27043078. PMCID: PMC7083263.

41. Farnell MB, Pearson RK, Sarr MG, DiMagno EP, Burgart LJ, Dahl TR, et al. 2005; A prospective randomized trial comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma. Surgery. 138:618–628. discussion 628–630. DOI: 10.1016/j.surg.2005.06.044. PMID: 16269290.

42. Nimura Y, Nagino M, Takao S, Takada T, Miyazaki K, Kawarada Y, et al. 2012; Standard versus extended lymphadenectomy in radical pancreatoduodenectomy for ductal adenocarcinoma of the head of the pancreas: long-term results of a Japanese multicenter randomized controlled trial. J Hepatobiliary Pancreat Sci. 19:230–241. DOI: 10.1007/s00534-011-0466-6. PMID: 22038501.

43. Jang JY, Kang MJ, Heo JS, Choi SH, Choi DW, Park SJ, et al. 2014; A prospective randomized controlled study comparing outcomes of standard resection and extended resection, including dissection of the nerve plexus and various lymph nodes, in patients with pancreatic head cancer. Ann Surg. 259:656–664. DOI: 10.1097/SLA.0000000000000384. PMID: 24368638.

44. Jang JY, Kang JS, Han Y, Heo JS, Choi SH, Choi DW, et al. 2017; Long-term outcomes and recurrence patterns of standard versus extended pancreatectomy for pancreatic head cancer: a multicenter prospective randomized controlled study. J Hepatobiliary Pancreat Sci. 24:426–433. DOI: 10.1002/jhbp.465. PMID: 28514000.

45. Ignjatovic I, Knezevic S, Knezevic D, Dugalic V, Micev M, Matic S, et al. 2017; Standard versus extended lymphadenectomy in radical surgical treatment for pancreatic head carcinoma. J BUON. 22:232–238. PMID: 28365959.

46. Svoronos C, Tsoulfas G, Katsourakis A, Noussios G, Chatzitheoklitos E, Marakis NG. 2014; Role of extended lymphadenectomy in the treatment of pancreatic head adenocarcinoma: review and meta-analysis. ANZ J Surg. 84:706–711. DOI: 10.1111/ans.12423. PMID: 24165093.

47. Wang W, He Y, Wu L, Ye L, Yao L, Tang Z. 2019; Efficacy of extended versus standard lymphadenectomy in pancreatoduodenectomy for pancreatic head adenocarcinoma. An update meta-analysis. Pancreatology. 19:1074–1080. DOI: 10.1016/j.pan.2019.10.003. PMID: 31668841.

48. Michalski CW, Kleeff J, Wente MN, Diener MK, Büchler MW, Friess H. 2007; Systematic review and meta-analysis of standard and extended lymphadenectomy in pancreaticoduodenectomy for pancreatic cancer. Br J Surg. 94:265–273. DOI: 10.1002/bjs.5716. PMID: 17318801.

49. Giovinazzo F, Turri G, Katz MH, Heaton N, Ahmed I. 2016; Meta-analysis of benefits of portal-superior mesenteric vein resection in pancreatic resection for ductal adenocarcinoma. Br J Surg. 103:179–191. DOI: 10.1002/bjs.9969. PMID: 26663252.

50. Peng C, Zhou D, Meng L, Cao Y, Zhang H, Pan Z, et al. 2019; The value of combined vein resection in pancreaticoduodenectomy for pancreatic head carcinoma: a meta-analysis. BMC Surg. 19:84. DOI: 10.1186/s12893-019-0540-6. PMID: 31286916. PMCID: PMC6615269.

51. Bell R, Ao BT, Ironside N, Bartlett A, Windsor JA, Pandanaboyana S. 2017; Meta-analysis and cost effective analysis of portal-superior mesenteric vein resection during pancreatoduodenectomy: impact on margin status and survival. Surg Oncol. 26:53–62. DOI: 10.1016/j.suronc.2016.12.007. PMID: 28317585.

52. Yu XZ, Li J, Fu DL, Di Y, Yang F, Hao SJ, et al. 2014; Benefit from synchronous portal-superior mesenteric vein resection during pancreaticoduodenectomy for cancer: a meta-analysis. Eur J Surg Oncol. 40:371–378. DOI: 10.1016/j.ejso.2014.01.010. PMID: 24560302.

53. Zhou Y, Zhang Z, Liu Y, Li B, Xu D. 2012; Pancreatectomy combined with superior mesenteric vein-portal vein resection for pancreatic cancer: a meta-analysis. World J Surg. 36:884–891. DOI: 10.1007/s00268-012-1461-z. PMID: 22350478.

54. Amano H, Miura F, Toyota N, Wada K, Katoh K, Hayano K, et al. 2009; Is pancreatectomy with arterial reconstruction a safe and useful procedure for locally advanced pancreatic cancer? J Hepatobiliary Pancreat Surg. 16:850–857. DOI: 10.1007/s00534-009-0190-7. PMID: 19844653.

55. Bockhorn M, Burdelski C, Bogoevski D, Sgourakis G, Yekebas EF, Izbicki JR. 2011; Arterial en bloc resection for pancreatic carcinoma. Br J Surg. 98:86–92. DOI: 10.1002/bjs.7270. PMID: 21136564.

56. Bachellier P, Rosso E, Lucescu I, Oussoultzoglou E, Tracey J, Pessaux P, et al. 2011; Is the need for an arterial resection a contraindication to pancreatic resection for locally advanced pancreatic adenocarcinoma? A case-matched controlled study. J Surg Oncol. 103:75–84. DOI: 10.1002/jso.21769. PMID: 21105000.

57. Mollberg N, Rahbari NN, Koch M, Hartwig W, Hoeger Y, Büchler MW, et al. 2011; Arterial resection during pancreatectomy for pancreatic cancer: a systematic review and meta-analysis. Ann Surg. 254:882–893. DOI: 10.1097/SLA.0b013e31823ac299. PMID: 22064622.

58. Małczak P, Sierżęga M, Stefura T, Kacprzyk A, Droś J, Skomarovska O, et al. 2020; Arterial resections in pancreatic cancer - systematic review and meta-analysis. HPB (Oxford). 22:961–968. DOI: 10.1016/j.hpb.2020.04.005. PMID: 32360186.

59. Haines M, Chua TC, Jamieson NB, Mittal A, Gill AJ, Samra JS. 2020; Pancreatoduodenectomy with arterial resection for locally advanced pancreatic cancer of the head: a systematic review. Pancreas. 49:621–628. DOI: 10.1097/MPA.0000000000001551. PMID: 32433398.

60. Wu X, Tao R, Lei R, Han B, Cheng D, Shen B, et al. 2010; Distal pancreatectomy combined with celiac axis resection in treatment of carcinoma of the body/tail of the pancreas: a single-center experience. Ann Surg Oncol. 17:1359–1366. DOI: 10.1245/s10434-009-0840-7. PMID: 20198445.

61. Beane JD, House MG, Pitt SC, Kilbane EM, Hall BL, Parmar AD, et al. 2015; Distal pancreatectomy with celiac axis resection: what are the added risks? HPB (Oxford). 17:777–784. DOI: 10.1111/hpb.12453. PMID: 26201994. PMCID: PMC4557651.

62. Yamamoto Y, Sakamoto Y, Ban D, Shimada K, Esaki M, Nara S, et al. 2012; Is celiac axis resection justified for T4 pancreatic body cancer? Surgery. 151:61–69. DOI: 10.1016/j.surg.2011.06.030. PMID: 22088810.

63. Peters NA, Javed AA, Cameron JL, Makary MA, Hirose K, Pawlik TM, et al. 2016; Modified Appleby procedure for pancreatic adenocarcinoma: does improved neoadjuvant therapy warrant such an aggressive approach? Ann Surg Oncol. 23:3757–3764. DOI: 10.1245/s10434-016-5303-3. PMID: 27328946.

64. Gong H, Ma R, Gong J, Cai C, Song Z, Xu B. 2016; Distal pancreatectomy with en bloc celiac axis resection for locally advanced pancreatic cancer: a systematic review and meta-analysis. Medicine (Baltimore). 95:e3061. DOI: 10.1097/MD.0000000000003061. PMID: 26962836. PMCID: PMC4998917.

65. Nigri G, Petrucciani N, Belloni E, Lucarini A, Aurello P, D'Angelo F, et al. 2021; Distal pancreatectomy with celiac axis resection: systematic review and meta-analysis. Cancers (Basel). 13:1967. DOI: 10.3390/cancers13081967. PMID: 33921838. PMCID: PMC8073522.

66. Storkholm JH, Burgdorf SK, Hansen CP. 2020; Distal pancreas-coeliac axis resection with preoperative selective embolization of the coeliac axis: a single high-volume centre experience. Langenbecks Arch Surg. 405:635–645. DOI: 10.1007/s00423-020-01919-7. PMID: 32683485.

67. Kawabata Y, Tanaka T, Nishi T, Monma H, Yano S, Tajima Y. 2012; Appraisal of a total meso-pancreatoduodenum excision with pancreaticoduodenectomy for pancreatic head carcinoma. Eur J Surg Oncol. 38:574–579. DOI: 10.1016/j.ejso.2012.04.007. PMID: 22575529.

68. Xu J, Tian X, Chen Y, Ma Y, Liu C, Tian L, et al. 2017; Total mesopancreas excision for the treatment of pancreatic head cancer. J Cancer. 8:3575–3584. DOI: 10.7150/jca.21341. PMID: 29151943. PMCID: PMC5687173.

69. Sugiyama M, Suzuki Y, Nakazato T, Yokoyama M, Kogure M, Abe N, et al. 2016; Intestinal derotation procedure for facilitating pancreatoduodenectomy. Surgery. 159:1325–1332. DOI: 10.1016/j.surg.2015.11.014. PMID: 26767309.

70. Aimoto T, Mizutani S, Kawano Y, Matsushita A, Yamashita N, Suzuki H, et al. 2013; Left posterior approach pancreaticoduodenectomy with total mesopancreas excision and circumferential lymphadenectomy around the superior mesenteric artery for pancreatic head carcinoma. J Nippon Med Sch. 80:438–445. DOI: 10.1272/jnms.80.438. PMID: 24419715.

71. Srinarmwong C, Luechakiettisak P, Prasitvilai W. 2008; Standard whipple's operation versus pylorus preserving pancreaticoduodenectomy: a randomized controlled trial study. J Med Assoc Thai. 91:693–698.

72. Tani M, Kawai M, Hirono S, Ina S, Miyazawa M, Fujita Y, et al. 2009; Pylorus-preserving pancreaticoduodenectomy versus conventional pancreaticoduodenectomy for pancreatic adenocarcinoma. Surg Today. 39:219–224. DOI: 10.1007/s00595-008-3847-y. PMID: 19280281.

73. Kawai M, Tani M, Hirono S, Okada K, Miyazawa M, Yamaue H. 2014; Pylorus-resecting pancreaticoduodenectomy offers long-term outcomes similar to those of pylorus-preserving pancreaticoduodenectomy: results of a prospective study. World J Surg. 38:1476–1483. DOI: 10.1007/s00268-013-2420-z. PMID: 24370543.

74. Iqbal N, Lovegrove RE, Tilney HS, Abraham AT, Bhattacharya S, Tekkis PP, et al. 2008; A comparison of pancreaticoduodenectomy with pylorus preserving pancreaticoduodenectomy: a meta-analysis of 2822 patients. Eur J Surg Oncol. 34:1237–1245. DOI: 10.1016/j.ejso.2007.12.004. PMID: 18242943.

75. Yang C, Wu HS, Chen XL, Wang CY, Gou SM, Xiao J, et al. 2014; Pylorus-preserving versus pylorus-resecting pancreaticoduodenectomy for periampullary and pancreatic carcinoma: a meta-analysis. PLoS One. 9:e90316. DOI: 10.1371/journal.pone.0090316. PMID: 24603478. PMCID: PMC3946060.

76. Hüttner FJ, Fitzmaurice C, Schwarzer G, Seiler CM, Antes G, Büchler MW, et al. 2016; Pylorus-preserving pancreaticoduodenectomy (pp Whipple) versus pancreaticoduodenectomy (classic Whipple) for surgical treatment of periampullary and pancreatic carcinoma. Cochrane Database Syst Rev. 2:CD006053. DOI: 10.1002/14651858.CD006053.pub6. PMID: 26905229. PMCID: PMC8255094.

77. Klaiber U, Probst P, Hüttner FJ, Bruckner T, Strobel O, Diener MK, et al. 2020; Randomized trial of pylorus-preserving vs. pylorus-resecting pancreatoduodenectomy: long-term morbidity and quality of life. J Gastrointest Surg. 24:341–352. DOI: 10.1007/s11605-018-04102-y. PMID: 30671796.

78. Fatima J, Schnelldorfer T, Barton J, Wood CM, Wiste HJ, Smyrk TC, et al. 2010; Pancreatoduodenectomy for ductal adenocarcinoma: implications of positive margin on survival. Arch Surg. 145:167–172. DOI: 10.1001/archsurg.2009.282. PMID: 20157085.

79. Pang TC, Wilson O, Argueta MA, Hugh TJ, Chou A, Samra JS, et al. 2014; Frozen section of the pancreatic neck margin in pancreatoduodenectomy for pancreatic adenocarcinoma is of limited utility. Pathology. 46:188–192. DOI: 10.1097/PAT.0000000000000072. PMID: 24614707.

80. Mathur A, Ross SB, Luberice K, Kurian T, Vice M, Toomey P, et al. 2014; Margin status impacts survival after pancreaticoduodenectomy but negative margins should not be pursued. Am Surg. 80:353–360. DOI: 10.1177/000313481408000416. PMID: 24887665.

81. Nitschke P, Volk A, Welsch T, Hackl J, Reissfelder C, Rahbari M, et al. 2017; Impact of intraoperative re-resection to achieve R0 status on survival in patients with pancreatic cancer: a single-center experience with 483 patients. Ann Surg. 265:1219–1225. DOI: 10.1097/SLA.0000000000001808. PMID: 27280512.

82. Dikmen K, Kerem M, Bostanci H, Sare M, Ekinci O. 2018; Intra-operative frozen section histology of the pancreatic resection margins and clinical outcome of patients with adenocarcinoma of the head of the pancreas undergoing pancreaticoduodenectomy. Med Sci Monit. 24:4905–4913. DOI: 10.12659/MSM.910279. PMID: 30007990. PMCID: PMC6067030.

83. Crippa S, Guarneri G, Belfiori G, Partelli S, Pagnanelli M, Gasparini G, et al. 2020; Positive neck margin at frozen section analysis is a significant predictor of tumour recurrence and poor survival after pancreatodudenectomy for pancreatic cancer. Eur J Surg Oncol. 46:1524–1531. DOI: 10.1016/j.ejso.2020.02.013. PMID: 32098733.

84. Barreto SG, Pandanaboyana S, Ironside N, Windsor JA. 2017; Does revision of resection margins based on frozen section improve overall survival following pancreatoduodenectomy for pancreatic ductal adenocarcinoma? A meta-analysis. HPB (Oxford). 19:573–579. DOI: 10.1016/j.hpb.2017.03.006. PMID: 28420560.

85. Petrucciani N, Nigri G, Debs T, Giannini G, Sborlini E, Antolino L, et al. 2016; Frozen section analysis of the pancreatic margin during pancreaticoduodenectomy for cancer: Does extending the resection to obtain a secondary R0 provide a survival benefit? Results of a systematic review. Pancreatology. 16:1037–1043. DOI: 10.1016/j.pan.2016.09.004. PMID: 27697467.

86. Strasberg SM, Drebin JA, Linehan D. 2003; Radical antegrade modular pancreatosplenectomy. Surgery. 133:521–527. DOI: 10.1067/msy.2003.146. PMID: 12773980.

87. Zhou Q, Fengwei-Gao , Gong J, Xie Q, Liu Y, Wang Q, et al. 2019; Assessement of postoperative long-term survival quality and complications associated with radical antegrade modular pancreatosplenectomy and distal pancreatectomy: a meta-analysis and systematic review. BMC Surg. 19:12. DOI: 10.1186/s12893-019-0476-x. PMID: 30691444. PMCID: PMC6348671.

88. Sham JG, Guo S, Ding D, Shao Z, Wright M, Jing W, et al. 2020; Radical antegrade modular pancreatosplenectomy versus standard distal pancreatosplenectomy for pancreatic cancer, a dual-institutional analysis. Chin Clin Oncol. 9:54. Erratum in: Chin Clin Oncol 2020;9:72. DOI: 10.21037/cco-20-6. PMID: 32576018.

89. Abe T, Ohuchida K, Miyasaka Y, Ohtsuka T, Oda Y, Nakamura M. 2016; Comparison of surgical outcomes between radical antegrade modular pancreatosplenectomy (RAMPS) and standard retrograde pancreatosplenectomy (SPRS) for left-sided pancreatic cancer. World J Surg. 40:2267–2275. DOI: 10.1007/s00268-016-3526-x. PMID: 27138881.

90. Grossman JG, Fields RC, Hawkins WG, Strasberg SM. 2016; Single institution results of radical antegrade modular pancreatosplenectomy for adenocarcinoma of the body and tail of pancreas in 78 patients. J Hepatobiliary Pancreat Sci. 23:432–441. DOI: 10.1002/jhbp.362. PMID: 27207482.

91. Kim EY, You YK, Kim DG, Hong TH. 2016; Initial experience with radical antegrade modular pancreatosplenectomy in a single institution. Ann Surg Treat Res. 91:29–36. DOI: 10.4174/astr.2016.91.1.29. PMID: 27433462. PMCID: PMC4942536.

92. Kawabata Y, Hayashi H, Kaji S, Fujii Y, Nishi T, Tajima Y. 2020; Laparoscopic versus open radical antegrade modular pancreatosplenectomy with artery-first approach in pancreatic cancer. Langenbecks Arch Surg. 405:647–656. DOI: 10.1007/s00423-020-01887-y. PMID: 32524466.

93. Kim HS, Hong TH, You YK, Park JS, Yoon DS. 2021; Radical antegrade modular pancreatosplenectomy (RAMPS) versus conventional distal pancreatectomy for left-sided pancreatic cancer: findings of a multicenter, retrospective, propensity score matching study. Surg Today. 51:1775–1786. DOI: 10.1007/s00595-021-02280-y. PMID: 33830293.

94. Lillemoe KD, Cameron JL, Hardacre JM, Sohn TA, Sauter PK, Coleman J, et al. 1999; Is prophylactic gastrojejunostomy indicated for unresectable periampullary cancer? A prospective randomized trial. Ann Surg. 230:322–328. DOI: 10.1097/00000658-199909000-00005. PMID: 10493479. PMCID: PMC1420877.

95. Wong YT, Brams DM, Munson L, Sanders L, Heiss F, Chase M, et al. 2002; Gastric outlet obstruction secondary to pancreatic cancer: surgical vs endoscopic palliation. Surg Endosc. 16:310–312. DOI: 10.1007/s00464-001-9061-2. PMID: 11967685.

96. Gurusamy KS, Kumar S, Davidson BR. 2013; Prophylactic gastrojejunostomy for unresectable periampullary carcinoma. Cochrane Database Syst Rev. 2013:CD008533. DOI: 10.1002/14651858.CD008533.pub3. PMID: 23450583. PMCID: PMC7173743.

97. Upchurch E, Ragusa M, Cirocchi R. 2018; Stent placement versus surgical palliation for adults with malignant gastric outlet obstruction. Cochrane Database Syst Rev. 5:CD012506. DOI: 10.1002/14651858.CD012506.pub2. PMID: 29845610. PMCID: PMC6494580.

98. Williamsson C, Wennerblom J, Tingstedt B, Jönsson C. 2016; A wait-and-see strategy with subsequent self-expanding metal stent on demand is superior to prophylactic bypass surgery for unresectable periampullary cancer. HPB (Oxford). 18:107–112. DOI: 10.1016/j.hpb.2015.08.009. PMID: 26776858. PMCID: PMC4750237.

99. Doi R, Kami K, Ito D, Fujimoto K, Kawaguchi Y, Wada M, et al. 2007; Prognostic implication of para-aortic lymph node metastasis in resectable pancreatic cancer. World J Surg. 31:147–154. DOI: 10.1007/s00268-005-0730-5. PMID: 17171496.

100. Schwarz L, Lupinacci RM, Svrcek M, Lesurtel M, Bubenheim M, Vuarnesson H, et al. 2014; Para-aortic lymph node sampling in pancreatic head adenocarcinoma. Br J Surg. 101:530–538. DOI: 10.1002/bjs.9444. PMID: 24633831.

101. Murakami Y, Uemura K, Sudo T, Hashimoto Y, Yuasa Y, Sueda T. 2010; Prognostic impact of para-aortic lymph node metastasis in pancreatic ductal adenocarcinoma. World J Surg. 34:1900–1907. DOI: 10.1007/s00268-010-0577-2. PMID: 20376442.

102. Sho M, Murakami Y, Motoi F, Satoi S, Matsumoto I, Kawai M, et al. 2015; Postoperative prognosis of pancreatic cancer with para-aortic lymph node metastasis: a multicenter study on 822 patients. J Gastroenterol. 50:694–702. DOI: 10.1007/s00535-014-1005-4. PMID: 25341657.

103. Hempel S, Plodeck V, Mierke F, Distler M, Aust DE, Saeger HD, et al. 2017; Para-aortic lymph node metastases in pancreatic cancer should not be considered a watershed for curative resection. Sci Rep. 7:7688. DOI: 10.1038/s41598-017-08165-w. PMID: 28794500. PMCID: PMC5550512.

104. Agalianos C, Gouvas N, Papaparaskeva K, Dervenis C. 2016; Positive para-aortic lymph nodes following pancreatectomy for pancreatic cancer. Systematic review and meta-analysis of impact on short term survival and association with clinicopathologic features. HPB (Oxford). 18:633–641. DOI: 10.1016/j.hpb.2016.04.007. PMID: 27485057. PMCID: PMC4972380.

105. Paiella S, Sandini M, Gianotti L, Butturini G, Salvia R, Bassi C. 2016; The prognostic impact of para-aortic lymph node metastasis in pancreatic cancer: a systematic review and meta-analysis. Eur J Surg Oncol. 42:616–624. DOI: 10.1016/j.ejso.2016.02.003. PMID: 26916137.

106. Asaoka T, Miyamoto A, Maeda S, Hama N, Tsujie M, Ikeda M, et al. 2018; CA19-9 level determines therapeutic modality in pancreatic cancer patients with para-aortic lymph node metastasis. Hepatobiliary Pancreat Dis Int. 17:75–80. DOI: 10.1016/j.hbpd.2018.01.004. PMID: 29428109.

107. Hackert T, Niesen W, Hinz U, Tjaden C, Strobel O, Ulrich A, et al. 2017; Radical surgery of oligometastatic pancreatic cancer. Eur J Surg Oncol. 43:358–363. DOI: 10.1016/j.ejso.2016.10.023. PMID: 27856064.

108. Zanini N, Lombardi R, Masetti M, Giordano M, Landolfo G, Jovine E. 2015; Surgery for isolated liver metastases from pancreatic cancer. Updates Surg. 67:19–25. DOI: 10.1007/s13304-015-0283-6. PMID: 25702263.

109. Dünschede F, Will L, von Langsdorf C, Möhler M, Galle PR, Otto G, et al. 2010; Treatment of metachronous and simultaneous liver metastases of pancreatic cancer. Eur Surg Res. 44:209–213. DOI: 10.1159/000313532. PMID: 20571276.

110. Yu X, Gu J, Fu D, Jin C. 2017; Dose surgical resection of hepatic metastases bring benefits to pancreatic ductal adenocarcinoma? A systematic review and meta-analysis. Int J Surg. 48:149–154. DOI: 10.1016/j.ijsu.2017.10.066. PMID: 29081375.

111. Marthey L, Sa-Cunha A, Blanc JF, Gauthier M, Cueff A, Francois E, et al. 2015; FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort. Ann Surg Oncol. 22:295–301. DOI: 10.1245/s10434-014-3898-9. PMID: 25037971.

112. Habermehl D, Kessel K, Welzel T, Hof H, Abdollahi A, Bergmann F, et al. 2012; Neoadjuvant chemoradiation with Gemcitabine for locally advanced pancreatic cancer. Radiat Oncol. 7:28. DOI: 10.1186/1748-717X-7-28. PMID: 22385572. PMCID: PMC3338091.

113. Polistina F, Di Natale G, Bonciarelli G, Ambrosino G, Frego M. 2014; Neoadjuvant strategies for pancreatic cancer. World J Gastroenterol. 20:9374–9383. DOI: 10.3748/wjg.v20.i28.9374. PMID: 25071332. PMCID: PMC4110569.

114. Nanda RH, El-Rayes B, Maithel SK, Landry J. 2015; Neoadjuvant modified FOLFIRINOX and chemoradiation therapy for locally advanced pancreatic cancer improves resectability. J Surg Oncol. 111:1028–1034. DOI: 10.1002/jso.23921. PMID: 26073887.

115. Gemenetzis G, Groot VP, Blair AB, Laheru DA, Zheng L, Narang AK, et al. 2019; Survival in locally advanced pancreatic cancer after neoadjuvant therapy and surgical resection. Ann Surg. 270:340–347. DOI: 10.1097/SLA.0000000000002753. PMID: 29596120. PMCID: PMC6985003.

116. Murphy JE, Wo JY, Ryan DP, Clark JW, Jiang W, Yeap BY, et al. 2019; Total neoadjuvant therapy With FOLFIRINOX in combination with losartan followed by chemoradiotherapy for locally advanced pancreatic cancer: a phase 2 clinical trial. JAMA Oncol. 5:1020–1027. DOI: 10.1001/jamaoncol.2019.0892. PMID: 31145418. PMCID: PMC6547247.

117. Doi R, Imamura M, Hosotani R, Imaizumi T, Hatori T, Takasaki K, et al. 2008; Surgery versus radiochemotherapy for resectable locally invasive pancreatic cancer: final results of a randomized multi-institutional trial. Surg Today. 38:1021–1028. DOI: 10.1007/s00595-007-3745-8. PMID: 18958561.

118. Gurusamy KS, Kumar S, Davidson BR, Fusai G. Resection versus other treatments for locally advanced pancreatic cancer. Cochrane Database Syst Rev. 2014; 2:CD010244. DOI: 10.1002/14651858.CD010244.pub2. PMID: 24578248.

119. Hirono S, Kawai M, Okada KI, Miyazawa M, Shimizu A, Kitahata Y, et al. 2017; Mesenteric approach during pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. Ann Gastroenterol Surg. 1:208–218. DOI: 10.1002/ags3.12013. PMID: 29863125. PMCID: PMC5881370.

120. Wang M, Zhang H, Zhu F, Peng F, Wang X, Shen M, et al. 2017; Pancreaticoduodenectomy for borderline resectable pancreatic head cancer with a modified artery-first approach technique. Hepatobiliary Pancreat Dis Int. 16:215–221. DOI: 10.1016/S1499-3872(16)60171-6. PMID: 28381388.

121. Kurosaki I, Minagawa M, Takano K, Takizawa K, Hatakeyama K. 2011; Left posterior approach to the superior mesenteric vascular pedicle in pancreaticoduodenectomy for cancer of the pancreatic head. JOP. 12:220–229. PMID: 21546696.

122. Pędziwiatr M, Pisarska M, Małczak P, Major P, Wierdak M, Radkowiak D, et al. 2017; Laparoscopic uncinate process first pancreatoduodenectomy-feasibility study of a modified 'artery first' approach to pancreatic head cancer. Langenbecks Arch Surg. 402:917–923. DOI: 10.1007/s00423-017-1597-2. PMID: 28699023. PMCID: PMC5563330.

123. Sabater L, Cugat E, Serrablo A, Suarez-Artacho G, Diez-Valladares L, Santoyo-Santoyo J, et al. 2019; Does the artery-first approach improve the rate of R0 resection in pancreatoduodenectomy?: A multicenter, randomized, controlled trial. Ann Surg. 270:738–746. DOI: 10.1097/SLA.0000000000003535. PMID: 31498183.